Pancreatic lipase is essential to break down fats into fatty acids and accounts for a majority of fatty acid digestion.1,2

Fat may be the most poorly absorbed macronutrient relative to carbohydrates and proteins

Conditions commonly associated with fat malabsorption3:

  • Cystic fibrosis
  • Pancreatitis
  • Pancreatic cancer
  • Crohn’s disease
  • Celiac disease
  • Other inflammatory bowel diseases
  • Gastric cancer
  • Surgery/trauma

Patients with compromised pancreatic output have a higher risk for fatty acid deficiencies in plasma and tissue, which may be related to a variety of adverse physiological effects, such as altered membrane and cellular functions.

REFERENCES
1. Whitcomb DC, Lowe ME. Human pancreatic digestive enzymes. Dig Dis Sci. 2007;52:1-17.
2. Carriere F, Barrowman JA, Verger R, Laugier R. Secretion and contribution of lipolysis of gastric and pancreatic lipases during a test meal in humans. Gastroenterology. 1993;105:876-888.
3. MedlinePlus Website. Malabsorption. https://medlineplus.gov/ency/article/000299.htm. Accessed October 16, 2017.

Close

This information is intended for
US healthcare professionals

Close
Close

You are now leaving the RELiZORB
product website to view the
Alcresta Therapeutics corporate website.